araag2/HINT huggingface dataset:
Clinical trial NCT01239173 (phase 3, status: terminated)
Conditions: posttraumatic stress disorder
ICD codes: F43.10, F43.11, F43.12
Drugs: avlocardyl, placebo, avlocardyl, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    study stopped by promoter for lack of inclusion
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients of French mother language

          -  Right-handed patients

          -  Signature of the consent

        Patients:

          -  Patients whose diagnosis of PTSD according to the criteria of the DSM IV-TR is
             established

          -  PTSD whose evolution is not chronic

          -  Established PTSD : Symptoms presents for at least 1 month

          -  PTSD consecutive to a unique traumatic event

        Controls :

          -  The healthy controls will have sudden a traumatism of the same nature or the nature
             comparable to that of the patients suffering from PTSD, but they will not have
             developed pathology

          -  Subjects having undergone a traumatism dating less than 3 months

          -  Examples of traumatic events: aggression, accident of the public highway, the
             occupational accident

        Exclusion Criteria:

          -  The PTSD consecutive to several traumatic events

          -  Patients treated by a substance crossing the blood-brain barrier (with the exception
             of the antidepressants of the family of the ISRS which can be indicated in the
             treatment of PTSD)

          -  Histories of epilepsy or significant loss of consciousness of any origin, including
             post-traumatic

          -  Any psychiatric or somatic significant pathology

          -  The psychiatric histories in particular of suicide attempt

          -  The pregnant or breast-feeding women

          -  Contraindications in the propanolol

          -  Consumption of psychoactive drugs detected in urines

          -  Excessive alcohol consumption

          -  The persons not being capable of understanding or of reading the information
             describing the study

          -  The patients refusing to sign the form of consent of participation for the study

          -  The left-handed or ambidextrous patients

          -  The patients without the general regime of the health insurance

          -  The patients under guardianship or incapable major

          -  The patients who will not be capable of supplying a documentary evidence of identity
             the day of the inclusion

          -  Contraindication in the practice of a MRI

          -  The patients or the controls refusing the medical and psychiatric balance assessment
             of screening cannot participate in the study

          -  Strong probability of not compliance to the protocol or of abandonment in the course
             of study

          -  Taking of a speechless medicine, in particular beta-blocking

          -  Participating in phase of exclusion from a previous study
Clinical trial NCT00300274 (phase 3, status: completed)
Conditions: graft rejection
ICD codes: T86.830, T86.820
Drugs: everolimus, mycophenolate mofetil, cyclosporine, corticosteroids
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, N[C@@H](CCCNC(N)=N)C(O)=O, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female cardiac recipients 18-70 years of age undergoing primary heart
             transplantation.

          -  The graft must be functional at time of randomization.

        Exclusion Criteria:

          -  Patients who are recipients of multiple solid organ transplants or tissue transplants
             or have previously received organ transplants.

          -  Patients who are recipients of ABO incompatible transplants.

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00663858 (phase 3, status: completed)
Conditions: benign prostatic hypertrophy
ICD codes: J35.3, J35.1, J35.2, N28.81, N62, N85.2, J34.3
Drugs: cetrorelix 78+78, cetrorelix 78 + placebo
SMILES: CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Benign Prostatic Hyperplasia, based on medical history

          -  Voiding symptoms

        Exclusion Criteria:

          -  Urgent need for prostate surgery or prior surgical treatment of the prostate or
             bladder

          -  Major organ dysfunction

          -  Eczema (atopic dermatitis) treated during the last 6 months

          -  Current or recent treatment with sexual hormone drugs or 5 α reductase inhibitors or
             botulinum toxin type a (Botox) within the last 6 months prior randomization or with α
             blockers or saw palmetto within the last 6 weeks prior to randomization

          -  Urologic disorders including neurogenic bladder dysfunction due to diabetes mellitus
             or documented neurologic disorder, urethral stricture disease or history of pelvic
             radiation therapy

          -  History of acute obstructive, infectious, or neurological disorders of the
             genitourinary tract within the last 3 months
Clinical trial NCT00408993 (phase 3, status: completed)
Conditions: diabetic neuropathies
ICD codes: G60.8
Drugs: duloxetine hydrochloride, placebo
SMILES: CNCC[C@H](OC1=CC=CC2=CC=CC=C12)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have pain due to bilateral peripheral neuropathy caused by Type I or Type II diabetes
             with the pain beginning in the feet and present for at least 6 months.

          -  May not be pregnant and agree to utilize medically acceptable and reliable means of
             birth control during participation in the study.

          -  Score of 4 or greater on the Brief Pain Inventory on the 24-hour average pain item.

        Exclusion Criteria:

          -  Glycosylated hemoglobin (A1C) > 12%

          -  Severe hepatic disease

          -  History of substance abuse or dependence within the past year, excluding nicotine and
             caffeine.

          -  Serious or unstable cardiovascular, hepatic (acute liver injury such as hepatitis or
             severe cirrhosis), kidney, respiratory, blood disorder, seizure disorder, problems
             with peripheral vascular disease, or other medical conditions or psychiatric
             conditions that would hinder your participation or likely to lead to hospitalization
             during the course of the study.

          -  Taking monoamine oxidase inhibitor (MAOI) within 14 days of starting the study or the
             potential need to take during or within 5 days after discontinuation from the study.

          -  Treatment of fluoxetine within 30 days of starting the study.

          -  Unstable blood sugar control and uncontrolled or poorly controlled hypertension.
Clinical trial NCT00385138 (phase 3, status: terminated)
Conditions: atherosclerosis, acute coronary syndrome (acs)
ICD codes: I67.2, I70.90, I70.91, I70.0, I70.1, I70.8, I25.83
Drugs: cangrelor, clopidogrel, placebo bolus & placebo infusion, placebo capsules - end of pci, placebo capsules - end of infusion
SMILES: CSCCNC1=C2N=CN([C@@H]3O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC(SCCC(F)(F)F)=N1, N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    insufficient evidence of the clinical effectiveness of cangrelor
  
Eligibility criteria:

        Inclusion Criteria:

        Angiography demonstrating atherosclerosis amenable to treatment by percutaneous coronary
        intervention (PCI) with or without stent implantation and diagnosis of Acute Coronary
        Syndrome (ACS) by elevated cardiac markers or ischemic chest discomfort w/electrocardiogram
        changes + age > 65 or diabetes.

        Exclusion Criteria:

          1. Not a candidate for PCI

          2. ST-segment elevation myocardial infarction (STEMI) within 48 hours of randomization

          3. Increased bleeding risk: ischemic stroke within the last year or any previous
             hemorrhagic stroke, intra-cranial tumor, cerebral arteriovenous malformation, or
             intracranial aneurysm; recent (<1 month) trauma or major surgery [including coronary
             artery bypass graft (CABG) surgery]; currently receiving warfarin, active bleeding

          4. Impaired hemostasis: known International Normalized Ratio (INR) >1.5 at screening;
             past or present bleeding disorder (including congenital bleeding disorders such as von
             Willebrand's disease or hemophilia, acquired bleeding disorders, and unexplained
             clinically significant bleeding disorders), thrombocytopenia (platelet count
             <100,000/µL) at screening

          5. Severe hypertension not adequately controlled by antihypertensive therapy at the time
             of randomization

          6. Receipt of fibrinolytic therapy in the 12 hours preceding randomization

          7. Receipt of any thienopyridine (clopidogrel or ticlopidine) in the 7 days preceding
             randomization

          8. Glycoprotein IIb/IIIa (GPI) Inhibitor usage within the previous 12 hours [applicable
             to unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) patients]
Clinical trial NCT01060072 (phase 3, status: completed)
Conditions: inflammation, pain
ICD codes: H01.9, H30.93, H05.00, H30.003, H30.013, H30.033, H30.103, N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: loteprednol etabonate, vehicle of loteprednol etabonate
SMILES: [H][C@@]12CC[C@](OC(=O)OCC)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects who are at least 18 years of age.

          -  Subjects who are candidates for routine, uncomplicated cataract surgery.

        Exclusion Criteria:

          -  Subjects who have known hypersensitivity or contraindication to the study drug or
             components.

          -  Subjects with a severe/serious ocular condition, or any other unstable medical
             condition, that in the investigator's opinion may preclude study treatment or
             follow-up.

          -  Subjects with elevated intraocular pressure (>/=21mm Hg), uncontrolled glaucoma, or
             being treated for glaucoma in the study eye.

          -  Subjects who are monocular or have pinholed Snellen visual acuity (VA) 20/200 or worse
             in the non-study eye.
Clinical trial NCT01168791 (phase 3, status: completed)
Conditions: soft tissue sarcoma
ICD codes: C46.1
Drugs: doxorubicin in combination with palifosfamide-tris, doxorubicin in combination with placebo
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Eligibility criteria:

        To be eligible, each patient must meet EACH of the following criteria:

          -  Age ≥18 years.

          -  Documented soft tissue sarcoma

          -  Metastatic disease for which the patient has not received any prior treatment, and for
             whom treatment with doxorubicin is considered medically acceptable.

          -  ECOG Performance Status of 0, 1 or 2

          -  Adequate bone marrow and organ function based on the results of protocol- specified
             laboratory tests

          -  Male and female patients must agree to use a highly reliable method of birth control
             during study participation.

          -  Able to provide informed consent

        To be eligible, each patient must meet NONE of the following criteria:

          -  Specific sarcoma histological subtypes including GIST and Ewing's sarcoma.

          -  Systemic therapy for the treatment of metastatic sarcoma, prior to or during the
             study. However, patients may have received neo-adjuvant/adjuvant Gemzar and Taxotere
             chemotherapy for their primary sarcoma, prior to the development of metastatic disease

          -  Any prior anthracycline use.

          -  Known allergy to any of the study drugs or their excipients.

          -  Any unstable or clinically significant concurrent medical condition that would, in the
             opinion of the investigator, jeopardize the safety of a patient and/or their
             compliance with the protocol, based on screening tests, physical examination and
             medical history (as specifically defined in the clinical protocol).

          -  Myocardial dysfunction defined as left ventricular ejection fraction (LVEF) <50%.

          -  Documented metastases to brain or meninges.

          -  Any malignancy other than sarcoma within the last 5 years prior to screening, with the
             exception of cervical carcinoma in situ, basal cell carcinoma, or superficial bladder
             tumors (Ta, Tis, or T1) that have been successfully and curatively treated with no
             evidence of recurrent or residual disease.

          -  Currently pregnant or nursing.

          -  Radiotherapy with curative intent within 4 weeks of first dose of study drug.
Clinical trial NCT00333775 (phase 3, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: docetaxel, placebo to bevacizumab, bevacizumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion criteria:

          -  Female patients ≥ 18 years of age.

          -  Human epidermal growth factor receptor 2 (HER2)-negative cancer of the breast with
             locally recurrent or metastatic disease, suitable for chemotherapy.

          -  No adjuvant chemotherapy within 6 months before randomization, and no taxane-based
             chemotherapy within 12 months before randomization.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

        Exclusion criteria:

          -  Previous chemotherapy for metastatic or locally recurrent breast cancer.

          -  Radiotherapy for treatment of metastatic disease.

          -  Other primary tumors within last 5 years, except for controlled limited basal cell or
             squamous cancer of the skin, or cancer in situ of the cervix.

          -  Spinal cord compression or brain metastases.

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to randomization.

          -  Inadequate bone marrow, liver, or renal function.

          -  Uncontrolled hypertension.
Clinical trial NCT00430651 (phase 3, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: docetaxel, carboplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed NSCLC.

          -  ECOG Performance Status 0-2.

          -  No previous treatment with Docetaxel.

          -  Measurable Disease.

          -  Brain metastases that have been treated with radiotherapy should be stable and
             asymptomatic.

          -  Adequate liver kidney and bone marrow function.

          -  Patients must be able to understand the nature of this study and give written informed
             consent.

        Exclusion Criteria:

          -  Active cardiac disease: unstable angina or onset of angina within last 3 months,
             myocardial infarction within 6 months, congestive heart failure > class II, cardiac
             ventricular arrhythmias requiring anti-arrhythmic therapy.

          -  Women who are pregnant or lactating.

          -  Unknown HIV, chronic hepatitis B or chronic hepatitis C infections.

          -  Serious neurologic or psychiatric disease.

          -  Second primary malignancy within the past 5 years, except nonmelanomas skin cancer or
             in situ carcinoma of the cervix.

          -  Active uncontrolled infection.
Clinical trial NCT01702532 (phase 3, status: completed)
Conditions: smoking cessation
ICD codes: Y36.881S, Y36.891S, Y36.880S, Y36.881A, Y36.881D, Y36.890S, Y36.891A
Drugs: nicotine
SMILES: CC(=O)NC1=CC=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  BMI within the range of 19-35 kg/m2;

          -  Current cigarette smokers who have smoked regularly daily for at least a year,

          -  Participants who smoke their first cigarette more than 30 minutes after waking up

        Exclusion Criteria:

          -  Known or suspected intolerance or hypersensitivity to nicotine (or closely related
             compounds) or any of the stated ingredients in formulation.

          -  Any participant whose CO level rises during the sequestration period (i.e., the
             subject's two expired CO assessments immediately prior to the provoked craving
             paradigm are higher than the mean baseline CO assessment) and, in the opinion of the
             investigator, may have smoked during that time.
Clinical trial NCT00158405 (phase 3, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: zidovudine (zdv), lamivudine (3tc), efavirenz (efv), ritonavir (nrv), indinavir (idv)
SMILES: CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O, NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1, FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent

          -  18 years old or more

          -  CD4 count between 150 and 350 per mm3 (or CD4 percentage between 12.5 and 20 percent)

          -  no past history of curative antiretroviral therapy

          -  residence in Abidjan

        Exclusion Criteria:

          -  pregnancy

          -  severe renal failure

          -  severe hepatic failure

          -  severe neuropsychiatric disease
Clinical trial NCT00004933 (phase 3, status: terminated)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: hydroxyurea, homoharringtonine
SMILES: NC(=O)NO, [H][C@@]1(OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)C(OC)=C[C@]23CCCN2CCC2=CC4=C(OCO4)C=C2[C@]13[H]
Reason stopped: 
    poor accrual
  
Eligibility criteria:

        1. Documentation of Disease:

             1.1 Diagnosis of Chronic Myelogenous Leukemia (CML) in chronic phase. Patients in
             either accelerated or blastic phases are not eligible. Clonal cytogenetic evolution
             alone does not exclude patients. See Appendix I for definitions of accelerated and
             blastic phases of CML.

             1.2 Patients in whom a Philadelphia chromosome [t(9;22)] is not detectable by
             cytogenetic studies are eligible if they meet one of the following criteria:

               -  BCR/ABL protein detectable by immunoblotting

               -  BCR/ABL rearrangement detectable by Southern blot analysis

               -  Polymerase chain reaction (PCR) positive fusion transcripts for BCR/ABL

               -  BCR/ABL translocation present by fluorescence in situ hybridization (FISH).

          2. Prior Treatment:

             2.1 No previous therapy with homoharringtonine (HHT)

             2.2 No more than six months cumulative (<180 days) of prior hydroxyurea (HU) therapy.
             However, patients may not have received more than 60 days of HU treatment after
             failing interferon. Patients with previous intolerance or failure to respond to HU are
             not eligible.

             2.3 Patients must have failed an adequate trial (5M units/m2/day) of alpha-Interferon
             (IFN) or IFN/ara-C to be eligible, as defined below (any ONE of the following):

               -  Failure to achieve a complete hematologic response after 6 months of IFN therapy.

               -  Failure to achieve any cytogenetic response (i.e., still 100% Ph+) after 12
                  months of IFN therapy.

               -  Intolerable adverse effects of IFN therapy after at least one month of IFN
                  treatment. Significant documented toxicity of ≥ grade 3 (using NCI Common
                  Toxicity Criteria guidelines) due to IFN is required.

               -  Loss of a prior hematologic remission or cytogenetic response to IFN.

               -  A two-fold increase in WBC count when compared to WBC count when IFN therapy was
                  initiated.

          3. Age ≥ 16 years

          4. Patients with uncontrolled tachyarrhythmias (such as, atrial fibrillation, paroxysmal
             supraventricular tachycardia, and ventricular tachycardias not adequately controlled)
             are not eligible.

          5. Non-pregnant and non-nursing. Treatment under this protocol would expose an unborn
             child to significant risks. Women and men of reproductive potential should agree to
             use an effective means of birth control.